Hosted on MSN

NDA preparation strategy 2026 check subject-wise strategy here

NDA Preparation Strategy 2026: NDA 1 2026 exam is scheduled for April 12, 2026. With only a few months left, candidates should start preparing for the exam. Begin by reviewing the latest syllabus and ...
Pharmabiz

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...
Yahoo Finance

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful ...
Targeted Oncology

NDA for Rusfertide Submitted to FDA for Polycythemia Vera

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
Nasdaq

Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position

On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Seeking Alpha

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...